Skip to content

Clinical trials

Phase 1 Lymphoma, T-Cell, Peripheral trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, T-Cell, Peripheral Phase: Phase 1 Country / region: United States Clear all

65 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20071
20081
20095
20106
20113
20125
20134
20143
20155
20162
20174
20193
20204
20211
20222
20233
20244
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed32
Terminated18
Recruiting7
Active, not recruiting4
Suspended2
Not yet recruiting1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)11
Acrotech Biopharma Inc.2
Barbara Ann Karmanos Cancer Institute2
Case Comprehensive Cancer Center2
City of Hope Medical Center2
Pfizer2
Seagen, a wholly owned subsidiary of Pfizer2
Stanford University2
Taiho Oncology, Inc.2
Washington University School of Medicine2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, T-Cell, Peripheral65
Lymphoma, T-Cell, Cutaneous35
Lymphoma, Large-Cell, Anaplastic31
Lymphoma, Large B-Cell, Diffuse30
Lymphoma, Non-Hodgkin27
Lymphoma, Extranodal NK-T-Cell26
Hodgkin Disease25
Immunoblastic Lymphadenopathy25
Leukemia, Lymphocytic, Chronic, B-Cell25
Mycosis Fungoides24

Trials

Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.